Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 15:13:8611-8627.
doi: 10.2147/CMAR.S328851. eCollection 2021.

Identification of Prognostic Biomarkers Among FAM83 Family Genes in Human Ovarian Cancer Through Bioinformatic Analysis and Experimental Verification

Shaochong Lin  1   2 , Junpeng Du  3 , Jun Hao  1 , Xiaohua Luo  1 , Han Wu  1 , Huifang Zhang  1 , Xinxin Zhao  1 , Lida Xu  1 , BaoJin Wang  1   2
Affiliations

Identification of Prognostic Biomarkers Among FAM83 Family Genes in Human Ovarian Cancer Through Bioinformatic Analysis and Experimental Verification

Shaochong Lin et al. Cancer Manag Res. .

Abstract

Purpose: Family with sequence similarity 83 (FAM83) is a newly discovered oncogene family, and the members of which can affect the prognosis of patients with malignant tumors via various mechanisms. However, the functions and molecular mechanisms of FAM83 genes in ovarian cancer (OC) have not yet been investigated. This study aimed to explore the clinical significance and prognostic value of FAM83 genes in OC.

Materials and methods: We used a series of bioinformatics databases (Oncomine, GEPIA, cBioPortal, Kaplan-Meier plotter, DAVID and TIMER) to investigate the expression status, prognostic value, genetic alteration and biological function of all eight FAM83 genes in OC. In addition, a tissue microarray cohort (TMA) comprising 99 ovarian tumor tissues and 19 normal ovarian tissues was used to validate the protein expression and clinicopathological significance of FAM83H.

Results: Several datasets demonstrated the mRNA levels of FAM83A/D/E/F/H were significantly higher in OC compared with that in normal tissue. Moreover, the upregulation of FAM83D/H has been mutually confirmed in the Oncomine and GEPIA datasets. Kaplan-Meier survival analysis indicated that the FAM83D/H upregulation could predict poor prognosis of OC patients who had shorter overall survival (OS) and progression-free survival (PFS). In addition, cBioportal analysis indicated that the genetic alterations of FAM83 genes might affect the survival outcomes of patients with OC. Furthermore, KEGG analysis suggested that FAM83D/H are involved in the progression of OC through the cell cycle signaling pathway, and they had significant co-expression relationship with cell cycle-related genes. Finally, immunohistochemistry analysis confirmed the high expression of FAM83H protein in OC tissue, suggesting that its expression is positively correlated with the FIGO stage and pathological subtype of OC.

Conclusion: This study elucidated the expression status and prognostic value of FAM83 genes in OC and identified that FAM83D/H might be potential targets for the prognostic monitoring and targeted therapy of OC.

Keywords: FAM83s; biomarker; immunohistochemistry; ovarian cancer; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Transcriptional level of FAM83 family members in various types of cancer (ONCOMINE).
Figure 2
Figure 2
The mRNA expression levels of FAM83 family members in 426 ovarian cancer tissues and 88 normal ovary tissues (GEPIA) (A–H).
Figure 3
Figure 3
FAM83 family genes alterations in ovarian cancer (cBioportal).
Figure 4
Figure 4
Prognostic value of FAM83s mRNA levels in patients with OC (OS in Kaplan–Meier plotter).
Figure 5
Figure 5
Prognostic value of FAM83s mRNA levels in patients with OC (PFS in Kaplan–Meier plotter).
Figure 6
Figure 6
Functional enrichment analysis of FAM83D and FAM83H in ovarian cancer.
Figure 7
Figure 7
Co-expression analysis of FAM83D/H and cell cycle pathway-related genes.
Figure 8
Figure 8
Correlation between FAM83D/H expression and immune infiltration.
Figure 9
Figure 9
IHC analysis and clinicopathological analysis of FAM83H in OC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492 - DOI - PubMed
    1. Kurnit KC, Fleming GF, Lengyel E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet Gynecol. 2021;137(1):108–121. doi:10.1097/AOG.0000000000004173 - DOI - PMC - PubMed
    1. Shimizu A, Sawada K, Kimura T. Pathophysiological role and potential therapeutic exploitation of exosomes in ovarian cancer. Cells. 2020;9(4):814. - PMC - PubMed
    1. Rottmann M, Burges A, Mahner S, et al. Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol. 2017;143(9):1833–1844. doi:10.1007/s00432-017-2422-6 - DOI - PubMed
    1. Salamini-Montemurri M, Lamas-Maceiras M, Barreiro-Alonso A, et al. The challenges and opportunities of LncRNAs in ovarian cancer research and clinical use. Cancers. 2020;12(4):1020. doi:10.3390/cancers12041020 - DOI - PMC - PubMed